Exhibit 99.1 Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates WAYNE, PA, November 6, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the third quarter of 2025. "Now that enrollment is complete, we're fully focused on completing the LOTUS trial, preparing for the data readout ...